BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34509167)

  • 21. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
    Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
    Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
    Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
    Chen D; Soh CK; Goh WH; Wang H
    J Med Chem; 2018 Feb; 61(4):1552-1575. PubMed ID: 29360358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
    Liu Y; Xia Q; Fang L
    Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
    Xie R; Li Y; Tang P; Yuan Q
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
    Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
    Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
    Wang J; Su M; Li T; Gao A; Yang W; Sheng L; Zang Y; Li J; Liu H
    Eur J Med Chem; 2017 Mar; 128():293-299. PubMed ID: 28213282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and Anticancer Activity of Benzimidazole/Benzoxazole Substituted Triazolotriazines in Hepatocellular Carcinoma.
    Dadashpour S; Küçükkılınç TT; Ercan A; Hosseinimehr SJ; Naderi N; Irannejad H
    Anticancer Agents Med Chem; 2019; 19(17):2120-2129. PubMed ID: 31393257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors.
    Gong G; Qi J; Lv Y; Dong S; Cao C; Li D; Zhao R; Li Z; Chen X
    Chem Pharm Bull (Tokyo); 2020; 68(5):466-472. PubMed ID: 32378544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
    Mao PT; He WB; Mai X; Feng LH; Li N; Liao YJ; Zhu CS; Li J; Chen T; Liu SH; Zhang QM; He L
    Bioorg Med Chem; 2022 Feb; 56():116599. PubMed ID: 35041998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma.
    Ahmed NM; Youns M; Soltan MK; Said AM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1110-1120. PubMed ID: 31117890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
    Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
    Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.